PRIM, S.A. (ES:PRM)
BME:PRM
Top Page
PRIM, S.A.
(BME:PRM)
Select Model
Select Model
Rating:74Outperform
Price Target:
€14.50
▲(9.43% Upside)
Action:ReiteratedDate:04/05/26
The score is driven primarily by strong underlying financials (especially the debt-free balance sheet and improved profitability) and supported by attractive valuation (low P/E and solid dividend yield). Offsetting these positives, technical indicators are neutral and cash-flow consistency has been uneven, limiting the overall rating.
Positive Factors
Debt-free balance sheet
Elimination of debt materially reduces financial risk and interest burden, giving durable flexibility for capital allocation, dividends or opportunistic M&A. Over the next 2–6 months this unlevered position supports resilience to shocks and strategic optionality.
Negative Factors
Uneven cash generation
Volatile operating and free cash flow, including prior negative periods and a material FCF decline in 2025 versus 2024, signals inconsistent cash conversion. This undermines capacity to fund capex, acquisitions or consistent dividends without rebuilding resilience in working-capital management.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
Elimination of debt materially reduces financial risk and interest burden, giving durable flexibility for capital allocation, dividends or opportunistic M&A. Over the next 2–6 months this unlevered position supports resilience to shocks and strategic optionality.
Read all positive factors
PRIM, S.A. (PRM) vs. iShares MSCI Spain ETF (EWP)
Market Cap
€225.42M
Dividend Yield3.37%
Average Volume (3M)3.97K
Price to Earnings (P/E)1346.1
Beta (1Y)0.31
Revenue GrowthN/A
EPS GrowthN/A
CountryES
Employees958
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)N/A
Shares Outstanding17,036,577
10 Day Avg. Volume4,234
30 Day Avg. Volume3,973
Financial Highlights & Ratios
PEG Ratio25.34
Price to Book (P/B)163.15
Price to Sales (P/S)89.18
P/FCF Ratio1.24K
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.16
Revenue Forecast (FY)€270.68M
PRIM, S.A. Business Overview & Revenue Model
Company Description
Prim, S.A., through its subsidiaries, designs, manufactures, and commercializes orthopedic products for physiotherapy, thalassotherapy, hydrotherapy, rehabilitation, spa, geriatrics, and support techniques in Spain and internationally. The company...
How the Company Makes Money
PRIM makes money primarily by selling healthcare products (including orthopedic, rehabilitation, and medical supply items) through a mix of channels that typically include direct sales to healthcare providers (e.g., hospitals and clinics), sales v...
PRIM, S.A. Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
90
Very Positive
Cash Flow
62
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 240.68M | 251.82M | 233.15M | 216.51M | 197.25M | 168.51M |
| Gross Profit | 117.99M | 127.01M | 112.62M | 45.30M | 94.56M | 83.08M |
| EBITDA | 25.26M | 33.94M | 26.23M | 28.05M | 19.71M | 30.18M |
| Net Income | 14.55M | 16.68M | 10.92M | 12.67M | 8.39M | 17.42M |
Balance Sheet | ||||||
| Total Assets | 207.94M | 196.53M | 190.28M | 200.10M | 184.99M | 179.85M |
| Cash, Cash Equivalents and Short-Term Investments | 13.47M | 23.03M | 13.75M | 13.25M | 14.94M | 36.54M |
| Total Debt | 17.23M | 16.28M | 18.50M | 25.48M | 22.07M | 19.07M |
| Total Liabilities | 75.24M | 58.89M | 61.34M | 74.28M | 65.28M | 58.38M |
| Stockholders Equity | 132.70M | 137.64M | 128.93M | 125.82M | 119.71M | 121.47M |
Cash Flow | ||||||
| Free Cash Flow | 25.68M | 18.14M | 10.76M | -20.09M | -7.02M | 13.87M |
| Operating Cash Flow | 36.66M | 30.46M | 22.11M | -11.33M | 4.89M | 26.30M |
| Investing Cash Flow | -10.74M | -10.07M | -7.59M | -3.67M | -14.10M | -8.70M |
| Financing Cash Flow | -27.67M | -11.62M | -11.32M | 10.46M | -12.19M | -15.09M |
PRIM, S.A. Technical Analysis
Positive
13.25
Price Trends
12.85
Positive
13.02
Positive
12.75
Positive
Market Momentum
0.06
Negative
58.42
Neutral
81.62
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ES:PRM, the sentiment is Positive. The current price of 13.25 is above the 20-day moving average (MA) of 12.72, above the 50-day MA of 12.85, and above the 200-day MA of 12.75, indicating a bullish trend. The MACD of 0.06 indicates Negative momentum. The RSI at 58.42 is Neutral, neither overbought nor oversold. The STOCH value of 81.62 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ES:PRM.
PRIM, S.A. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | €225.42M | 1,346.06 | ― | 3.37% | ― | ― | |
67 Neutral | €813.54M | 15.29 | 45.95% | 3.31% | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | €209.08M | 41.66 | 2.03% | 1.91% | -1.19% | -54.66% | |
46 Neutral | €223.94M | -88.77 | -2.58% | ― | ― | 36.23% | |
43 Neutral | €218.06M | -2.22 | -9.43% | ― | 15.90% | 37.03% |
* Healthcare Sector Average
ES:PRM
PRIM, S.A.
13.30
3.94
42.12%
ES:CBAV
Clinica Baviera
49.90
16.91
51.25%
ES:RJF
LABORATORIO REIG JOFRE
2.56
-0.14
-5.29%
ES:ORY
Oryzon Genomics SA
2.84
0.06
2.16%
ES:ATRY
Atrys Health SA
2.87
0.02
0.70%
ES:LAB
Labiana Health SA
4.66
1.87
67.26%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.